These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23331434)

  • 1. Alternate-day dosing with statins.
    Marcus FI; Baumgarten AJ; Fritz WL; Nolan PE
    Am J Med; 2013 Feb; 126(2):99-104. PubMed ID: 23331434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.
    Mackie BD; Satija S; Nell C; Miller J; Sperling LS
    Am J Cardiol; 2007 Jan; 99(2):291. PubMed ID: 17223437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers.
    Li JJ; Yang P; Liu J; Jia YJ; Li ZC; Guo YL; Wu NQ; Tang YD; Jiang LX
    Clin Chim Acta; 2012 Jan; 413(1-2):139-42. PubMed ID: 21983163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
    Plakogiannis R; Cohen H
    Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.
    Ferrer-García JC; Pérez-Silvestre J; Martínez-Mir I; Herrera-Ballester A
    Acta Diabetol; 2006 Nov; 43(3):75-8. PubMed ID: 17143784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
    Faltaos DW; Urien S; Carreau V; Chauvenet M; Hulot JS; Giral P; Bruckert E; Lechat P
    Fundam Clin Pharmacol; 2006 Jun; 20(3):321-30. PubMed ID: 16671968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
    Gadarla M; Kearns AK; Thompson PD
    Am J Cardiol; 2008 Jun; 101(12):1747-8. PubMed ID: 18549851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of nonprescriptive factors on low-density lipoprotein cholesterol reduction with statins.
    Frolkis JP; Pearce GL; Sprecher DL
    Am J Cardiol; 2004 Nov; 94(10):1310-2. PubMed ID: 15541255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared].
    Kostner KM; Kostner GM
    Wien Klin Wochenschr; 1998 Oct; 110(18):625-30. PubMed ID: 9816634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.
    Awad K; Mikhailidis DP; Toth PP; Jones SR; Moriarty P; Lip GYH; Muntner P; Catapano AL; Pencina MJ; Rosenson RS; Rysz J; Banach M;
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):419-431. PubMed ID: 28741244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC; Otto C; Parhofer KG
    Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
    Pattanaik S; Malhotra S; Sharma YP; Pandhi P
    J Cardiovasc Pharmacol; 2012 May; 59(5):479-84. PubMed ID: 22569288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternate-day dosing of statins for secondary prevention of coronary artery disease/The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Celik M; Celik T
    Anadolu Kardiyol Derg; 2009 Jun; 9(3):253; author reply 253-4. PubMed ID: 19520663
    [No Abstract]   [Full Text] [Related]  

  • 20. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.